Skip to main content
CURX logo
CURX
(NASDAQ)
Curanex Pharmaceuticals Inc
$5.04-- (--)
Loading... - Market loading

Curanex Pharmaceuticals (CURX) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Curanex Pharmaceuticals Inc
CURXNasdaq Stock MarketHealthcareBiotechnology

About Curanex Pharmaceuticals

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.

Company Information

CEOJun Liu
Founded2018
IPO DateAugust 26, 2025
Employees6
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone718 673 6078
Address
2 Jericho Plaza, Suite 101B Jericho, New York 11753 United States

Corporate Identifiers

CIK0002025942
CUSIP23126K106
ISINUS23126K1060
EIN83-0741390
SIC2834

Leadership Team & Key Executives

Jun Liu
Chief Executive Officer, President and Chairman
Dian Ying Jing
Secretary
Haiyan Yang
Chief Financial Officer and Treasurer
Dr. Liqin Xie Ph.D.
Chief Operating Officer
Dr. Ning Zhang Ph.D.
Chief Technology Officer
Dr. Huijuan Zhong Ph.D.
Chief Science Officer and Director